Loading…

Structural basis for α-conotoxin potency and selectivity

This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs. Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α 6β 2∗ (∗ indicates the poss...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2009-08, Vol.17 (16), p.5894-5899
Main Authors: Turner, Matt, Eidemiller, Seth, Martin, Bryan, Narver, Andrew, Marshall, Joshua, Zemp, Logan, Cornell, Kenneth A., McIntosh, J.M., McDougal, Owen M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3
cites cdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3
container_end_page 5899
container_issue 16
container_start_page 5894
container_title Bioorganic & medicinal chemistry
container_volume 17
creator Turner, Matt
Eidemiller, Seth
Martin, Bryan
Narver, Andrew
Marshall, Joshua
Zemp, Logan
Cornell, Kenneth A.
McIntosh, J.M.
McDougal, Owen M.
description This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs. Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α 6β 2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α 6β 2 nAChRs structure and function, but it does not discriminate among closely related α 6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α 6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α 6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional 1H NMR spectroscopy to 0.13 ± 0.09 Ǻ backbone and 0.45 ± 0.08 Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α 6β 2 and α 3β 2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α 6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease.
doi_str_mv 10.1016/j.bmc.2009.07.005
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2754775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089609006506</els_id><sourcerecordid>19628399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</originalsourceid><addsrcrecordid>eNp9kM1OAyEYRYnR2PrzAG7MbFzOCAwzQExMTONf0sSFuibAgNK0QwO0sY_li_hM0rSpunHDF8K9hy8HgDMEKwRRezmp1ExXGEJeQVpB2OyBISItKeuao30whLxlJWS8HYCjGCcQQkw4OgQDxFvMas6HgD-nsNBpEeS0UDK6WFgfiq_PUvveJ__h-mLuk-n1qpB9V0QzNTq5pUurE3Bg5TSa0-08Bq93ty-jh3L8dP84uhmXmhCWSs0t7pRUnTYWGYggYTSfxrKGadkqrbFpOqTy1cg8JOGmodgqSpqadaY-Btcb7nyhZiZj-pSXFfPgZjKshJdO_H3p3bt480uBaUMobTIAbQA6-BiDsbsugmLtUUxE9ijWHgWkInvMnfPfn_40tuJy4GIbkFHLqQ2y1y7uchjlFOZr0NUmZ7KipTNBRO2yTtO5kE2Kzrt_1vgGBjOTog</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Structural basis for α-conotoxin potency and selectivity</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Turner, Matt ; Eidemiller, Seth ; Martin, Bryan ; Narver, Andrew ; Marshall, Joshua ; Zemp, Logan ; Cornell, Kenneth A. ; McIntosh, J.M. ; McDougal, Owen M.</creator><creatorcontrib>Turner, Matt ; Eidemiller, Seth ; Martin, Bryan ; Narver, Andrew ; Marshall, Joshua ; Zemp, Logan ; Cornell, Kenneth A. ; McIntosh, J.M. ; McDougal, Owen M.</creatorcontrib><description>This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs. Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α 6β 2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α 6β 2 nAChRs structure and function, but it does not discriminate among closely related α 6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α 6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α 6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional 1H NMR spectroscopy to 0.13 ± 0.09 Ǻ backbone and 0.45 ± 0.08 Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α 6β 2 and α 3β 2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α 6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2009.07.005</identifier><identifier>PMID: 19628399</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Amino Acid Sequence ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Biological and medical sciences ; Conotoxin ; Conotoxins - chemistry ; Conotoxins - pharmacology ; Humans ; Medical sciences ; Molecular Conformation ; Molecular Sequence Data ; Neuropharmacology ; Nicotinic acetylcholine receptor ; Nicotinic Antagonists - chemistry ; Nicotinic Antagonists - pharmacology ; NMR solution structure ; Parkinson Disease - physiopathology ; Parkinson’s disease ; Pharmacology. Drug treatments ; Protein Binding ; Protein Isoforms ; Receptors, Nicotinic - chemistry ; Receptors, Nicotinic - metabolism</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2009-08, Vol.17 (16), p.5894-5899</ispartof><rights>2009</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</citedby><cites>FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21839295$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19628399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turner, Matt</creatorcontrib><creatorcontrib>Eidemiller, Seth</creatorcontrib><creatorcontrib>Martin, Bryan</creatorcontrib><creatorcontrib>Narver, Andrew</creatorcontrib><creatorcontrib>Marshall, Joshua</creatorcontrib><creatorcontrib>Zemp, Logan</creatorcontrib><creatorcontrib>Cornell, Kenneth A.</creatorcontrib><creatorcontrib>McIntosh, J.M.</creatorcontrib><creatorcontrib>McDougal, Owen M.</creatorcontrib><title>Structural basis for α-conotoxin potency and selectivity</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs. Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α 6β 2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α 6β 2 nAChRs structure and function, but it does not discriminate among closely related α 6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α 6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α 6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional 1H NMR spectroscopy to 0.13 ± 0.09 Ǻ backbone and 0.45 ± 0.08 Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α 6β 2 and α 3β 2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α 6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease.</description><subject>Amino Acid Sequence</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Biological and medical sciences</subject><subject>Conotoxin</subject><subject>Conotoxins - chemistry</subject><subject>Conotoxins - pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Molecular Conformation</subject><subject>Molecular Sequence Data</subject><subject>Neuropharmacology</subject><subject>Nicotinic acetylcholine receptor</subject><subject>Nicotinic Antagonists - chemistry</subject><subject>Nicotinic Antagonists - pharmacology</subject><subject>NMR solution structure</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson’s disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Binding</subject><subject>Protein Isoforms</subject><subject>Receptors, Nicotinic - chemistry</subject><subject>Receptors, Nicotinic - metabolism</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OAyEYRYnR2PrzAG7MbFzOCAwzQExMTONf0sSFuibAgNK0QwO0sY_li_hM0rSpunHDF8K9hy8HgDMEKwRRezmp1ExXGEJeQVpB2OyBISItKeuao30whLxlJWS8HYCjGCcQQkw4OgQDxFvMas6HgD-nsNBpEeS0UDK6WFgfiq_PUvveJ__h-mLuk-n1qpB9V0QzNTq5pUurE3Bg5TSa0-08Bq93ty-jh3L8dP84uhmXmhCWSs0t7pRUnTYWGYggYTSfxrKGadkqrbFpOqTy1cg8JOGmodgqSpqadaY-Btcb7nyhZiZj-pSXFfPgZjKshJdO_H3p3bt480uBaUMobTIAbQA6-BiDsbsugmLtUUxE9ijWHgWkInvMnfPfn_40tuJy4GIbkFHLqQ2y1y7uchjlFOZr0NUmZ7KipTNBRO2yTtO5kE2Kzrt_1vgGBjOTog</recordid><startdate>20090815</startdate><enddate>20090815</enddate><creator>Turner, Matt</creator><creator>Eidemiller, Seth</creator><creator>Martin, Bryan</creator><creator>Narver, Andrew</creator><creator>Marshall, Joshua</creator><creator>Zemp, Logan</creator><creator>Cornell, Kenneth A.</creator><creator>McIntosh, J.M.</creator><creator>McDougal, Owen M.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20090815</creationdate><title>Structural basis for α-conotoxin potency and selectivity</title><author>Turner, Matt ; Eidemiller, Seth ; Martin, Bryan ; Narver, Andrew ; Marshall, Joshua ; Zemp, Logan ; Cornell, Kenneth A. ; McIntosh, J.M. ; McDougal, Owen M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Amino Acid Sequence</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Biological and medical sciences</topic><topic>Conotoxin</topic><topic>Conotoxins - chemistry</topic><topic>Conotoxins - pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Molecular Conformation</topic><topic>Molecular Sequence Data</topic><topic>Neuropharmacology</topic><topic>Nicotinic acetylcholine receptor</topic><topic>Nicotinic Antagonists - chemistry</topic><topic>Nicotinic Antagonists - pharmacology</topic><topic>NMR solution structure</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson’s disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Binding</topic><topic>Protein Isoforms</topic><topic>Receptors, Nicotinic - chemistry</topic><topic>Receptors, Nicotinic - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turner, Matt</creatorcontrib><creatorcontrib>Eidemiller, Seth</creatorcontrib><creatorcontrib>Martin, Bryan</creatorcontrib><creatorcontrib>Narver, Andrew</creatorcontrib><creatorcontrib>Marshall, Joshua</creatorcontrib><creatorcontrib>Zemp, Logan</creatorcontrib><creatorcontrib>Cornell, Kenneth A.</creatorcontrib><creatorcontrib>McIntosh, J.M.</creatorcontrib><creatorcontrib>McDougal, Owen M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turner, Matt</au><au>Eidemiller, Seth</au><au>Martin, Bryan</au><au>Narver, Andrew</au><au>Marshall, Joshua</au><au>Zemp, Logan</au><au>Cornell, Kenneth A.</au><au>McIntosh, J.M.</au><au>McDougal, Owen M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structural basis for α-conotoxin potency and selectivity</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2009-08-15</date><risdate>2009</risdate><volume>17</volume><issue>16</issue><spage>5894</spage><epage>5899</epage><pages>5894-5899</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>This manuscript provides the solution structure of α-conotoxin MII[E11A] and compares surface electrostatic maps for α-conotoxins that selectively inhibit α3β2 versus α6β2 nAChRs. Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α 6β 2∗ (∗ indicates the possible presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α 6β 2 nAChRs structure and function, but it does not discriminate among closely related α 6∗ nAChR subtypes. Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an analog with 500–5300-fold discrimination between α 6∗ subtypes found in both human and non-human primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the high affinity α 6 nAChR, a subtype that is selectively lost in Parkinson’s disease. Here, we present the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional 1H NMR spectroscopy to 0.13 ± 0.09 Ǻ backbone and 0.45 ± 0.08 Ǻ heavy atom root-mean-square deviation from mean structure. Structural comparisons suggest that the increased hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be responsible for its exceptionally high affinity for α6α4β2∗ nAChR as well as discrimination between α 6β 2 and α 3β 2 containing nAChRs. This finding may enable the rational design of novel peptide analogs that demonstrate enhanced specificity for α 6∗ nAChR subunit interfaces and provide a means to better understand nAChR structural determinants that modulate brain dopamine levels and the pathophysiology of Parkinson’s disease.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>19628399</pmid><doi>10.1016/j.bmc.2009.07.005</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2009-08, Vol.17 (16), p.5894-5899
issn 0968-0896
1464-3391
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2754775
source ScienceDirect Freedom Collection 2022-2024
subjects Amino Acid Sequence
Anticonvulsants. Antiepileptics. Antiparkinson agents
Biological and medical sciences
Conotoxin
Conotoxins - chemistry
Conotoxins - pharmacology
Humans
Medical sciences
Molecular Conformation
Molecular Sequence Data
Neuropharmacology
Nicotinic acetylcholine receptor
Nicotinic Antagonists - chemistry
Nicotinic Antagonists - pharmacology
NMR solution structure
Parkinson Disease - physiopathology
Parkinson’s disease
Pharmacology. Drug treatments
Protein Binding
Protein Isoforms
Receptors, Nicotinic - chemistry
Receptors, Nicotinic - metabolism
title Structural basis for α-conotoxin potency and selectivity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A35%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structural%20basis%20for%20%CE%B1-conotoxin%20potency%20and%20selectivity&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Turner,%20Matt&rft.date=2009-08-15&rft.volume=17&rft.issue=16&rft.spage=5894&rft.epage=5899&rft.pages=5894-5899&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2009.07.005&rft_dat=%3Cpubmed_cross%3E19628399%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-c9f2dbabdcef1e010487010ef858ca6bcc2e5d1b858ea1b8a49e572fb74538de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19628399&rfr_iscdi=true